KynderMed will leverage new and proprietary insights into helping reduce the incidence of preterm births resulting from the reduction of melatonin.
We have developed the product, validated the technology in two small human trials, held an informal meeting with the FDA who are quite supportive, created a world class leadership team, secured a manufacturer and locked in a favorable product cost, and developed a detailed roadmap to market
All that remains to gain FDA approval is a few tweaks to the sleep mask and small pivotal clinical trial
KynderMed is currently raising the requisite funding to take the KynderMed solution through the final FDA approval process.
If you are a qualified investor and have an interest in learning more, please contact:
(617) 461 6654